Visualization of Cathepsin Activity Using ProSense 680 Agent from Well to Cell to Animal
12 December 2012
In this application note, the cathepsin-activatable ProSense 680 near-infrared (NIR) imaging agent was assessed and validated for use throughout the drug discovery process, from biochemistry to cellular assays to in vivo testing, using HT-29 colorectal cancer cells and 5-Fluorouracil (5-FU) treatment. ProSense 680 was visualized in these studies using the Operetta® High Content Imaging System and FMT® 2500 Fluorescence Tomography In Vivo Imaging System. Using the same agent in translational studies ensures that biological interactions are comparable.